Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Oronsky

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
Neuro-Oncology|January 16, 2016
Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastasesMichelle M Kim, Hemant Parmar, Yue Cao, et al.
Clinical Colorectal Cancer|December 18, 2022
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal CancerTony R Reid, Nacer Abrouk, Scott Caroen, et al.
Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.
Oncoimmunology|September 20, 2018
A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)Christopher Larson, Bryan Oronsky, Gina Varner, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
Translational Oncology|April 27, 2018
A Review of Clinical Radioprotection and Chemoprotection for Oral MucositisBryan Oronsky, Sharad Goyal, Michelle M Kim, et al.
Clinical and Translational Science|June 29, 2023
Data Management 101 for drug developers: A peek behind the curtainBryan Oronsky, Erica Burbano, Meaghan Stirn, et al.
Case Reports in Oncology|November 25, 2015
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine TumorCorey A Carter, Aiste Degesys, Bryan Oronsky, et al.
Drugs|March 15, 2023
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic InflammationNanthini Jayabalan, Bryan Oronsky, Pedro Cabrales, et al.
International Medical Case Reports Journal|December 22, 2022
Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001Terese Catherine Hammond, Raymond C Lee, Bryan Oronsky, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Neuro-Oncology|January 16, 2016
Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastasesMichelle M Kim, Hemant Parmar, Yue Cao, et al.
Clinical Colorectal Cancer|December 18, 2022
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal CancerTony R Reid, Nacer Abrouk, Scott Caroen, et al.
Expert Review of Hematology|April 28, 2017
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injuryPedro Cabrales, Scott Caroen, Arnold Oronsky, et al.
Oncoimmunology|September 20, 2018
A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)Christopher Larson, Bryan Oronsky, Gina Varner, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
Translational Oncology|April 27, 2018
A Review of Clinical Radioprotection and Chemoprotection for Oral MucositisBryan Oronsky, Sharad Goyal, Michelle M Kim, et al.
Clinical and Translational Science|June 29, 2023
Data Management 101 for drug developers: A peek behind the curtainBryan Oronsky, Erica Burbano, Meaghan Stirn, et al.
Case Reports in Oncology|November 25, 2015
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine TumorCorey A Carter, Aiste Degesys, Bryan Oronsky, et al.
Drugs|March 15, 2023
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic InflammationNanthini Jayabalan, Bryan Oronsky, Pedro Cabrales, et al.
International Medical Case Reports Journal|December 22, 2022
Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001Terese Catherine Hammond, Raymond C Lee, Bryan Oronsky, et al.
Pageof 12